evipedia.ai
← Back

Selegiline for Health & Longevity

Evidence Review created on 09/28/2026 using AI4L / Opus 5.5

Also known as: L-Deprenyl, Deprenyl, (−)-Deprenyl, Selegiline Hydrochloride, Eldepryl, Zelapar, Emsam, Jumex, Anipryl

Motivation

Selegiline (also called L-deprenyl) is a prescription medication used for decades in Parkinson’s disease and, as a transdermal patch, in depression. It permanently blocks one of the enzymes that breaks down dopamine, the brain chemical that drives movement, motivation and reward. Its appeal to longevity-minded adults lies in an unusual combination: an approved, inexpensive, long-established drug that has been tested again and again for its effect on lifespan in animals.

Interest began in the 1980s, when the drug’s Hungarian inventor studied whether small, regular doses could slow brain aging and lengthen life in elderly rats. Research groups in Canada, Japan, Germany and the United States then ran their own animal lifespan studies, and a veterinary version was developed for age-related mental decline in dogs. Human studies, by contrast, have enrolled people with brain diseases or depression rather than healthy aging adults.

This review examines what is known about selegiline’s benefits, risks, dosing and monitoring for health-focused adults considering it for brain health and longevity, and separates what human trials show from what rests on animal data alone.

Benefits - Risks - Protocol - Conclusion

This section lists expert articles and narrative reviews that give a high-level overview of selegiline as a candidate longevity drug.

Content from Peter Attia, Rhonda Patrick, Andrew Huberman and Chris Kresser is not included: web and on-site searches found no article or episode discussing selegiline or deprenyl by name. Lifespan.io mentions deprenyl only once, in a list of candidate dog interventions, without an overview.

Grokipedia

Selegiline

A broad encyclopedia-style overview of uses, pharmacology, adverse effects, interactions and history, with a dedicated subsection on longevity claims based on rodent studies.

Examine

No Examine article on selegiline exists. Examine.com does not typically cover prescription medications, and selegiline is available only by prescription.

ConsumerLab

No ConsumerLab article on selegiline exists. ConsumerLab does not typically cover prescription medications; selegiline appears only incidentally in reports on other products.

Systematic Reviews

This section lists systematic reviews and meta-analyses covering selegiline’s lifespan, psychiatric, Parkinson’s and dementia evidence, including safety and mortality.

Mechanism of Action

Selegiline, a propargylamine (a chemical group that binds enzymes permanently), irreversibly blocks monoamine oxidase B (MAO-B, an enzyme that breaks down dopamine and phenylethylamine). Dopamine therefore lasts longer in the striatum (the brain’s movement hub), easing Parkinson’s symptoms. At oral doses up to 10 mg/day it largely spares monoamine oxidase A (MAO-A, the gut and brain enzyme that clears serotonin, norepinephrine and dietary tyramine, a blood-pressure-raising compound in aged foods); at about 20 mg/day or more, or when a transdermal patch bypasses first-pass metabolism (gut and liver breakdown before a drug reaches the blood), brain MAO-A is also blocked, producing antidepressant effects.

Explanations for the animal lifespan findings compete:

  • MAO-B route: less dopamine breakdown yields less hydrogen peroxide in aging neurons.
  • Enhancer effect: Knoll’s group (the inventor’s) argues very low doses amplify catecholamine (dopamine and norepinephrine) release independently of MAO-B (Knoll & Miklya, 2016).
  • Antioxidant and anti-apoptotic: raised superoxide dismutase (SOD) and catalase (antioxidant enzymes) and less apoptosis (programmed cell death) (Kitani et al., 2002).
  • Against the MAO-B route: only female hamsters lived longer despite equal inhibition in both sexes (Stoll et al., 1997).

Oral bioavailability is about 10%, elimination half-life about 1.5 hours, and food raises absorption roughly threefold (Mahmood, 1997). The fat-soluble drug enters the brain readily. CYP2B6, CYP3A4 and CYP2A6 (liver drug-processing enzymes, CYP2B6 dominant) metabolize it (Benetton et al., 2007) into desmethylselegiline, l-methamphetamine and l-amphetamine. Brain MAO-B regenerates with a half-time of about 40 days (Fowler et al., 1994).

Historical Context & Evolution

Selegiline was synthesized in the early 1960s at the Hungarian company Chinoin by Zoltán Ecseri and József Knoll, originally as a “psychic energizer” antidepressant (Miklya, 2016). After two forms of monoamine oxidase were identified, Knoll showed (Knoll & Magyar, 1972) that the drug selectively blocked the B form and, unlike older drugs of its class, did not trigger dangerous blood-pressure surges after tyramine-rich foods such as aged cheese — the “cheese effect”.

In the 1970s Walther Birkmayer in Vienna added it to levodopa for Parkinson’s disease, and a 1985 long-term cohort co-authored with Knoll reported longer survival with the combination (Birkmayer et al., 1985). UK approval followed in 1982 and US approval in 1989, the year the DATATOP trial suggested it might slow Parkinson’s progression (Parkinson Study Group, 1989).

Knoll’s 1988 rat lifespan study (Knoll, 1988), followed by replications in Canada (Milgram et al., 1990) and Japan (Kitani et al., 1993), brought selegiline into the 1990s “smart drug” and life-extension movements, and a veterinary product (Anipryl) was approved for canine cognitive dysfunction. Opinion then shifted: longer follow-up attributed most of the Parkinson’s benefit to symptom relief (Parkinson Study Group, 1993), and a 1995 UK trial reported higher mortality with selegiline plus levodopa (Lees, 1995), a finding pooled analyses did not confirm (Macleod et al., 2005). The animal lifespan data were never refuted; a 2025 meta-analysis reassessed them and called for human studies (Bene, 2025). A transdermal patch for depression (Emsam) was approved in 2006.

Expected Benefits

High 🟩 🟩 🟩

Depressive Symptoms

At doses that also block MAO-A in the brain, selegiline raises serotonin, norepinephrine and dopamine, and the transdermal patch is approved for major depression. A meta-analysis of randomized trials found clear improvement over placebo, strongest in atypical depression (with oversleeping, overeating and mood reactivity) (Rossano et al., 2023); a six-week trial in 177 outpatients showed benefit from week one (Bodkin & Amsterdam, 2002). The pivotal patch trials were sponsored by the manufacturer, Somerset Pharmaceuticals. Oral 10 mg/day showed no antidepressant effect in an early trial (Mendis et al., 1981).

Magnitude: Standardized mean difference (SMD, effect size in standard-deviation units) −0.96, with a 95% CI (confidence interval, the range likely to hold the true effect) of −1.78 to −0.14; response risk ratio (RR, how many times more likely an outcome is) 1.61 (95% CI 1.20–2.15), and 2.23 in atypical depression.

Parkinson’s Disease Symptoms and Delayed Need for Levodopa ⭕️ Not Central to Health & Longevity

This benefit bears on symptom control in Parkinson’s disease rather than on healthy aging. In the DATATOP trial of 800 untreated patients, 10 mg/day delayed the disability that prompts levodopa (the standard dopamine-replacement drug) (Parkinson Study Group, 1993). A systematic review of 38 studies, pooling 23 in meta-analyses, found symptom-score gains that grew with treatment duration (Wang et al., 2023). A Cochrane review judged the effect symptomatic rather than disease-slowing (Macleod et al., 2005).

Magnitude: Hazard ratio (HR, the relative rate of an event over time) 0.50 (95% CI 0.41–0.62) for needing levodopa, about a nine-month median delay; Unified Parkinson’s Disease Rating Scale (UPDRS, a standard symptom score) mean difference −11.06 points at 60 months.

Narcolepsy Symptoms ⭕️ Not Central to Health & Longevity

This benefit bears on narcolepsy (a disorder of sudden, uncontrollable daytime sleep), not on healthy aging. Two small placebo-controlled trials found dose-dependent reductions in sleep attacks and cataplexy (sudden emotion-triggered muscle weakness) at 20–40 mg/day (Hublin et al., 1994; Mayer et al., 1995). These doses are no longer MAO-B selective and required a low-tyramine diet.

Magnitude: At 40 mg/day, 36% fewer daytime sleep episodes and 89% fewer cataplexy attacks than placebo in 17 patients.

Medium 🟩 🟩

Functional Recovery After Stroke ⭕️ Not Central to Health & Longevity

This benefit bears on rehabilitation after stroke rather than on healthy aging. In a small phase II trial, 5 mg twice daily for three months, started within 48 hours of a hemispheric stroke, improved neurological recovery versus placebo (Sivenius et al., 2001). Only 20 of 24 patients were analyzed, and disability and motor scales showed non-significant trends. Co-author Heinonen worked for Orion Pharma, a selegiline manufacturer (Heinonen & Myllylä, 1998). The proposed mechanism is dopamine-supported brain plasticity during rehabilitation.

Magnitude: Scandinavian Stroke Scale improvement significantly greater than placebo at three months (p = 0.019, meaning chance alone is unlikely); the trial reports no effect-size figure.

Low 🟩

Cognition and Alzheimer’s Disease Progression ⚠️ Conflicted

In 341 patients, selegiline delayed death, institutionalization or severe dementia only after baseline adjustment (Sano et al., 1997). A Cochrane review found small short-term memory gains (Birks & Flicker, 2003); aged rats and dogs learned better (Brandeis et al., 1991; Milgram et al., 1993). Net: no clinically meaningful dementia benefit.

Magnitude: Median 655 versus 440 days to the combined endpoint (adjusted analysis only); cognition SMD 0.39 (95% CI 0.07–0.72) at 4–6 weeks.

Attention and ADHD Symptoms ⚠️ Conflicted

In attention-deficit/hyperactivity disorder (ADHD), pooled placebo comparisons were negative, yet head-to-head trials matched methylphenidate (a standard stimulant) (Rossano et al., 2023). A crossover trial (drug and placebo given in turn) in children with Tourette’s syndrome missed its primary endpoint (Feigin et al., 1996). Net: attention benefit unproven.

Magnitude: Mean improvement 1.3 points (95% CI −2.7 to 5.3) on the DuPaul attention scale, not statistically significant.

Speculative 🟨

Lifespan Extension ⚠️ Conflicted

A meta-analysis of 22 rodent experiments found longer mean lifespan, larger with higher doses and later starts (Bene, 2025); some mouse data were null (Ingram et al., 1993). Net: consistent animal-only signal.

Restored Sexual Activity in Aging Animals

Old male rats given selegiline regained full sexual activity, 64 of 66 versus none on saline (Knoll, 1988), attributed to preserved striatal dopamine function. The basis is animal data only.

Antioxidant Defense and Tumor Suppression

Treated rats had higher brain superoxide dismutase and catalase activity (Kitani et al., 1994) and fewer sarcomas (connective-tissue cancers), 11 of 40 versus 20 of 40 (Knoll et al., 2017). Basis: animal data only.

Benefit-Modifying Factors

  • Genetic variation: No gene variant has been shown to predict benefit. Reduced-function CYP2B6 variants could raise exposure to the parent drug, which is the more MAO-B-selective species, but this has not been tested clinically.
  • Baseline biomarkers: No blood marker predicts a longevity response. In trials, larger effects appeared where dopamine signaling was already impaired (Parkinson’s disease) or depressive symptoms were atypical; people with normal mood and motor function may notice little.
  • Sex: Hamster lifespan gains appeared in females only (Stoll et al., 1997), while rat gains appeared in both sexes (Kitani et al., 2005). Sex differences in human benefit have not been studied; oral contraceptives sharply raise drug exposure.
  • Pre-existing conditions: Parkinson’s disease, depression (especially atypical) and narcolepsy show benefit; Alzheimer’s disease shows little. Healthy adults have no outcome data.
  • Age: In animals, lifespan effects were larger when treatment started later in life (Bene, 2025). Brain MAO-B activity rises with age, so older adults may have more enzyme activity to block.

Potential Risks & Side Effects

High 🟥 🟥 🟥

Insomnia and Overstimulation

Selegiline is metabolized to l-methamphetamine and l-amphetamine and boosts dopamine, both of which can delay sleep. In a meta-analysis of ten randomized trials, insomnia was clearly more frequent than with placebo (Rossano et al., 2023). With the patch, insomnia was dose-related in a review of Somerset Pharmaceuticals’ development-program data (Robinson & Amsterdam, 2008). It is usually mild and reversible, and is reduced by morning dosing.

Magnitude: RR 1.61 (95% CI 1.19–2.17) versus placebo across 1,768 participants.

Hallucinations, Confusion and Agitation

Added dopamine stimulation can cause neuropsychiatric effects, most often in older adults and in Parkinson’s patients also taking levodopa. A Parkinson’s meta-analysis found more neuropsychiatric adverse events than placebo (Wang et al., 2023), and France’s national database of reported drug side effects showed psychiatric reactions reported more often than with other Parkinson’s drugs (Montastruc et al., 2000). Effects typically resolve with dose reduction.

Magnitude: 31.6% versus 26.7% with placebo; odds ratio (OR, the relative odds of an event) 1.36 (95% CI 1.06–1.75).

Orthostatic Hypotension

Orthostatic hypotension (a blood-pressure drop on standing that causes dizziness or fainting) is a recognized effect. On head-up tilt, 9 of 16 Parkinson’s patients taking selegiline with levodopa had selective, often severe drops, versus none of 9 on levodopa alone (Churchyard et al., 1997); a second cohort confirmed it and showed full reversal within seven days of stopping (Churchyard et al., 1999). High-dose use lowered standing systolic pressure by 15% (Sunderland et al., 1994).

Magnitude: Marked tilt-induced hypotension in 56% (9 of 16) versus 0% (0 of 9); two patients lost consciousness.

Dry Mouth

Dry mouth is one of the few adverse effects that clearly separated from placebo in pooled psychiatric trials (Rossano et al., 2023). It is mild and reversible but, if persistent, can raise the risk of tooth decay and gum disease.

Magnitude: RR 1.58 (95% CI 1.03–2.43) across six trials and 1,134 participants.

Application-Site Skin Reactions

This risk applies only to the transdermal patch. Redness, itching and rash at the patch site were the most common adverse effect of the transdermal form and were dose-related (Robinson & Amsterdam, 2008; Rossano et al., 2023). Reactions are usually mild and resolve after removal.

Magnitude: RR 1.81 (95% CI 1.40–2.33) across six trials and 1,662 participants.

Medium 🟥 🟥

Positive Amphetamine Drug Screens

Selegiline’s main urinary metabolite is l-methamphetamine, with l-amphetamine also present (Shin, 1997). Standard immunoassay screens (antibody-based rapid urine tests) can therefore read positive for methamphetamine, as in a forensic case where only chiral testing (which tells the drug’s mirror-image forms apart) identified legitimate use (Shin et al., 2021). This matters for workplace, sports and legal testing.

Magnitude: Urinary metabolites, chiefly l-methamphetamine, account for 44–58% of a 2.5–10 mg dose within two days, so screens can read positive with any regular use; the literature reports no figure for how often screens turn positive.

Cardiac Rhythm Disturbances

Amphetamine-type metabolites and added catecholamine activity may disturb heart rhythm. In the randomized DATATOP trial, non-life-threatening arrhythmias, mostly a slow heart rate with impaired electrical conduction, occurred more often in deprenyl-treated patients (Parkinson Study Group, 1993). A manufacturer-authored safety review lists benign arrhythmias among frequent adverse events (Heinonen & Myllylä, 1998), and a case report described atrial fibrillation (an irregular, often rapid heartbeat) attributed to the drug (Duarte et al., 1996). The trial signal was of borderline statistical significance and has not been replicated.

Magnitude: Arrhythmias in 8 of 399 deprenyl-treated versus 1 of 401 other patients (2.0% versus 0.2%; p = 0.045) over about 14 months in early Parkinson’s disease.

Low 🟥

Excess Mortality ⚠️ Conflicted

An open-label (unblinded) UK trial reported more deaths with selegiline plus levodopa (Lees, 1995), possibly from combination-induced drops in standing blood pressure (Churchyard et al., 1997). Neither a Cochrane review (Macleod et al., 2005) nor 13-year follow-up (Marras et al., 2005) found excess deaths. Net: no consistent mortality signal.

Magnitude: Mortality ratio (death rate relative to levodopa alone) 1.57 (95% CI 1.09–2.30) in the single UK trial versus a pooled OR of 1.15 (95% CI 0.92–1.44) across ten trials.

Worsened Levodopa Dyskinesias ⚠️ Conflicted

Dyskinesias (involuntary writhing movements) from levodopa can intensify when selegiline is added. The UK trial found more disabling dyskinesias (Lees, 1995), but a Cochrane review found no difference (Macleod et al., 2005). Net: a possible risk with levodopa only, not established.

Magnitude: Pooled dyskinesia OR 0.97 (95% CI 0.76–1.25) in early Parkinson’s disease; the UK trial gave no pooled figure.

Serotonin Toxicity With Serotonergic Drugs

Serotonin syndrome (agitation, fever, tremor and muscle rigidity from excess serotonin) can occur with antidepressants or certain opioids. A survey of 4,568 Parkinson’s patients on selegiline plus an antidepressant found rare cases (Richard et al., 1997).

Magnitude: 0.24% had possible serotonin syndrome and 0.04% serious symptoms; no deaths.

Hypertensive Reactions at Higher Exposure

Above oral 10 mg/day, MAO-A blockade grows and dietary tyramine can raise blood pressure (Sunderland et al., 1994). Oral contraceptives raise exposure 10- to 20-fold (Laine et al., 1999). Patch trials at 6 mg/24 h without diet saw no reactions (Robinson & Amsterdam, 2008).

Magnitude: No hypertensive reactions among 2,036 patch-treated patients; risk rises at oral doses of about 20 mg/day or more; the literature gives no incidence figure.

Impulse-Control Problems

Dopamine-boosting drugs can trigger compulsive gambling, shopping or hypersexuality. In a Swedish national registry of 55,235 Parkinson’s patients, monoamine oxidase B inhibitor use predicted new gambling disorder (Wolfschlag et al., 2025). Data are class-level, not selegiline-specific.

Magnitude: Frequency ratio (how much more common the disorder was among users) 1.8 (p = 0.006) for incident gambling disorder with MAO-B inhibitors.

Melanoma Signal in Parkinson’s Disease

Labels advise regular skin checks because melanoma (a serious skin cancer) is more common in Parkinson’s disease. A treated trial cohort had 3.6-fold the expected rate (Constantinescu et al., 2014). No study ties this to selegiline itself.

Magnitude: Standardized event ratio (observed versus expected cases) 3.6 (95% CI 2.2–5.6) in treated Parkinson’s patients; no selegiline-specific figure exists.

Suicidality in Young Adults

The patch carries the antidepressant class warning on suicidal thinking. A US Food and Drug Administration analysis of 372 trials found raised risk under age 25 and lower risk at 65 and over (Stone et al., 2009). No selegiline-specific signal is reported.

Magnitude: OR 2.30 (95% CI 1.04–5.09) for suicidal behavior under 25; OR 0.06 at 65 and over.

Nausea ⚠️ Conflicted

A manufacturer-authored safety review lists nausea among the most frequent adverse events of selegiline alone, and with constipation when combined with levodopa (Heinonen & Myllylä, 1998). Pooled psychiatric trials found no significant excess over placebo (Rossano et al., 2023). Net: an occasional, usually mild effect without consistent excess over placebo.

Magnitude: Pooled psychiatric trials showed no significant difference from placebo, while uncontrolled Parkinson’s data list nausea as frequent; the literature reports no pooled incidence figure.

Speculative 🟨

Shortened Lifespan at Excessive Doses

In rats, 0.25–0.5 mg/kg extended lifespan while 1.0 mg/kg tended to shorten it (Kitani et al., 2005), suggesting a bell-shaped dose response. The basis is animal data only.

Stimulant Misuse Potential

Amphetamine-type metabolites raise a theoretical concern about misuse or dependence. The l-isomers are much weaker stimulants than illicit d-forms, and no dependence has been documented; the basis is mechanistic only.

Risk-Modifying Factors

  • Genetic polymorphisms: Reduced-function CYP2B6 variants may raise selegiline exposure and erode MAO-B selectivity. No genotype-guided dosing exists, and no study has linked a variant to adverse events.
  • Baseline blood pressure: Low resting pressure or an existing orthostatic drop raises fainting and fall risk; uncontrolled high pressure raises risk from tyramine, decongestants and stimulants.
  • Sex and hormones: Oral contraceptives raised selegiline exposure 10- to 20-fold in women (Laine et al., 1999), whereas menopausal hormone therapy did not meaningfully change it (Palovaara et al., 2002).
  • Pre-existing conditions: Parkinson’s disease on levodopa, bipolar disorder (risk of mania), psychosis, pheochromocytoma (an adrenaline-secreting tumor), and liver or kidney impairment increase adverse-event risk.
  • Age: Adults over 65 have more hallucinations and orthostatic hypotension, and patch labeling caps the dose at 6 mg/24 h in this group. Under 25, the antidepressant suicidality warning applies.

Key Interactions & Contraindications

  • Opioid analgesics (meperidine, tramadol, methadone, tapentadol): Absolute contraindication. Risk of serotonin syndrome and severe, sometimes fatal, reactions reported with meperidine. Non-serotonergic pain relief is used instead, with 14 days’ separation after stopping selegiline.
  • Antidepressants — SSRIs (selective serotonin reuptake inhibitors: fluoxetine, sertraline), SNRIs (serotonin–norepinephrine reuptake inhibitors: venlafaxine), tricyclics (older antidepressants: amitriptyline), mirtazapine, bupropion: Contraindicated with the patch; caution at low oral doses. Consequence: serotonin toxicity or hypertension. Mitigation: 2-week washout (5 weeks after fluoxetine).
  • Other monoamine oxidase inhibitors (phenelzine, rasagiline, linezolid, intravenous methylene blue): Absolute contraindication. Consequence: hypertensive crisis (a dangerous blood-pressure surge) or serotonin toxicity. Mitigation: at least 14 days between agents.
  • Oral contraceptives (ethinyl estradiol with levonorgestrel or gestodene): Caution. Consequence: 10- to 20-fold higher selegiline exposure and loss of selectivity. Mitigation: dose reduction or non-hormonal contraception.
  • Levodopa and dopamine agonists (drugs that directly stimulate dopamine receptors: carbidopa-levodopa, pramipexole, ropinirole): Monitor. Consequence: added dyskinesias, hallucinations and orthostatic hypotension. Mitigation: levodopa is often reduced by 10–30% when selegiline is added.
  • Anticonvulsants (seizure medications: carbamazepine, oxcarbazepine): Contraindicated with the patch per labeling. Consequence: markedly raised selegiline levels. Mitigation: alternative anticonvulsant.
  • Prescription stimulants (amphetamine, methylphenidate): Caution. Consequence: hypertension, tachycardia (rapid heart rate) and agitation. Mitigation: the combination is generally not used, or blood pressure is closely monitored.
  • Over-the-counter cough suppressant dextromethorphan: Contraindicated. Consequence: serotonin toxicity and brief psychotic reactions. Mitigation: non-serotonergic cough remedies such as honey or guaifenesin.
  • Over-the-counter decongestants and diet aids (pseudoephedrine, phenylephrine): Caution; avoid at non-selective doses. Consequence: blood-pressure spikes. Mitigation: saline nasal spray; home blood-pressure checks if used.
  • Serotonergic supplements (St John’s wort, 5-hydroxytryptophan, L-tryptophan, S-adenosylmethionine): Avoid. Consequence: serotonin toxicity. Mitigation: a washout of at least 2 weeks before selegiline is started.
  • Phenylethylamine and sympathomimetic (adrenaline-like) supplements (phenylethylamine, bitter orange/synephrine, yohimbe, ephedra): Avoid. Consequence: MAO-B normally clears phenylethylamine, so levels surge, causing hypertension, palpitations and anxiety. Mitigation: such pre-workout and “focus” products are excluded.
  • Dopamine-precursor supplements (L-tyrosine, Mucuna pruriens containing L-DOPA, natural levodopa): Monitor; additive effect. Consequence: insomnia, dyskinesias and hallucinations. Mitigation: high-dose use is avoided or the precursor dose reduced.
  • Blood-pressure-lowering supplements (hibiscus, aged garlic extract, beetroot nitrate): Monitor; additive effect. Consequence: worsened orthostatic hypotension and dizziness. Mitigation: standing blood pressure is rechecked after they are added.
  • Tyramine-rich foods (aged cheese, cured meats, tap beer, soy sauce): Caution only above oral 10 mg/day or patch 6 mg/24 h. Consequence: hypertensive crisis. Mitigation: low-tyramine diet with patch 9–12 mg/24 h or oral ≥20 mg/day, continued 2 weeks after stopping.
  • General anesthesia and elective surgery: Caution. Consequence: interactions with anesthetic agents and opioids, blood-pressure instability. Mitigation: patch labeling advises stopping 10 days before elective surgery; anesthetists are informed.

Populations who should avoid Selegiline:

  • People taking any contraindicated drug listed above, or within 14 days of stopping one (5 weeks for fluoxetine)
  • Pheochromocytoma
  • Children under 12 years (patch)
  • Uncontrolled hypertension (e.g., sustained blood pressure ≥160/100 mmHg)
  • Bipolar disorder without mood-stabilizer treatment, or a history of drug-induced mania
  • Active psychosis or current hallucinations
  • Pregnancy and breastfeeding (insufficient safety data)
  • Severe liver impairment (Child-Pugh class C, the most severe liver-function grade) or, for the orally disintegrating tablet, severe kidney impairment (creatinine clearance, a kidney-filtration measure, <30 mL/min)
  • Symptomatic orthostatic hypotension (systolic drop ≥20 mmHg on standing)
  • Elective surgery scheduled within 10 days

Risk Mitigation Strategies

  • Lowest effective oral dose: Keeping oral intake at or below 10 mg/day (longevity protocols typically use 1–5 mg) preserves MAO-B selectivity and prevents tyramine reactions and serotonin toxicity seen at non-selective doses.
  • Morning dosing: Taking the dose before noon limits insomnia and overstimulation from amphetamine-type metabolites.
  • Orthostatic blood-pressure checks: Lying and standing blood pressure at baseline, 2 weeks and 3 months; a systolic drop of 20 mmHg or more prompts dose reduction to prevent falls and fainting.
  • Interaction screening and wallet card: Reviewing prescriptions, over-the-counter drugs and supplements before starting, and carrying a card naming selegiline, prevents serotonin syndrome from meperidine, tramadol or dextromethorphan in emergencies.
  • Low-tyramine diet at higher exposure: Required with patch doses of 9 mg/24 h or more, oral doses of about 20 mg/day or more, or oral contraceptives, and for 2 weeks after stopping, to prevent hypertensive crisis.
  • Levodopa adjustment: In Parkinson’s disease, levodopa is commonly reduced by 10–30% when selegiline is added to limit dyskinesias and hallucinations.
  • Patch-site rotation: Rotating daily among upper torso, thigh and upper arm, and avoiding heat sources, reduces application-site skin reactions.
  • Annual skin examination: A yearly full-skin examination, especially in Parkinson’s disease, catches melanoma early.
  • Drug-test documentation: Carrying a prescription record, and requesting chiral confirmation testing, prevents a positive amphetamine screen from being misread as illicit use.
  • Mood tracking: Under 25 or with depression history, a validated mood questionnaire at baseline and monthly for 2 months detects emerging suicidal thinking or mania.

Therapeutic Protocol

  • Parkinson’s disease (conventional neurology): 5 mg orally with breakfast and 5 mg with lunch (10 mg/day), the regimen used by the Parkinson Study Group in the DATATOP trial (Parkinson Study Group, 1989).
  • Orally disintegrating tablet (Zelapar): 1.25 mg dissolved on the tongue before breakfast, rising to 2.5 mg after 6 weeks if needed; bypassing first-pass metabolism makes 1.25 mg roughly comparable to 10 mg of conventional tablets.
  • Depression (psychiatry): Emsam patch 6 mg/24 h, raised in 3 mg/24 h steps at intervals of at least 2 weeks to a maximum of 12 mg/24 h (Robinson & Amsterdam, 2008).
  • Longevity low dose (Life Extension Foundation): The Foundation has suggested 5 mg twice weekly, while some advisors used 5 mg daily after age 45 (Life Extension, 1999). The Foundation sells supplements, not selegiline.
  • Enhancer approach (Knoll): Knoll’s group advocated a small daily dose from the start of middle age, based on rat studies (Miklya, 2016); no human dose has been validated for longevity.
  • Alternative MAO-B inhibitor: Rasagiline 1 mg/day is a related irreversible MAO-B inhibitor without amphetamine-type metabolites; it has far less animal lifespan data.
  • Time of day: Morning dosing is standard to limit insomnia; taking it consistently with or without food matters, because food raises absorption about threefold (Mahmood, 1997).
  • Half-life: The parent drug’s half-life is about 1.5 hours and lengthens roughly fourfold with repeated dosing, but MAO-B blockade persists: brain enzyme recovers with a half-time of about 40 days (Fowler et al., 1994).
  • Single or split dosing: Parkinson’s regimens split 10 mg into morning and midday doses; low-dose longevity regimens use one morning dose daily or 2–3 times weekly, since irreversible inhibition allows intermittent dosing.
  • Genetic polymorphisms: Reduced-function CYP2B6 variants could raise exposure, but no genotype-guided dosing exists; standard low-dose starts cover this uncertainty.
  • Sex differences: Women taking oral contraceptives face 10- to 20-fold higher exposure, so lower doses or non-hormonal contraception are used; menopausal hormone therapy needs no adjustment.
  • Age: Adults over 65 start at the lowest dose, and patch labeling limits them to 6 mg/24 h; in animals, later starts produced larger lifespan effects (Bene, 2025).
  • Baseline biomarkers: Low resting blood pressure or an existing orthostatic drop favors the lowest dose or intermittent dosing; no biomarker predicts a longevity response.
  • Pre-existing conditions: Parkinson’s patients on levodopa usually need levodopa reduction; people with depression are dosed via the patch under psychiatric care; in bipolar disorder, protocols pair it with a mood stabilizer.

Discontinuation & Cycling

  • Lifelong or short-term: Longevity use is open-ended and long-term by intent; Parkinson’s use is typically lifelong; depression treatment usually continues 6–12 months after response.
  • Withdrawal effects: Low doses cause no classic withdrawal syndrome. In advanced Parkinson’s disease, stopping worsened motor function in 13 of 16 patients (Churchyard et al., 1997); depressive symptoms can return after the patch is stopped.
  • Tapering: Parkinson’s and patch users are usually tapered over 1–2 weeks; low-dose longevity users can simply stop. Orthostatic hypotension resolved within seven days of stopping (Churchyard et al., 1999).
  • Lingering enzyme blockade: Because MAO-B takes weeks to regenerate, interaction precautions with serotonergic drugs and opioids continue for 14 days after the last dose.
  • Cycling: No evidence shows that cycling maintains efficacy, and no tolerance has been documented. Intermittent schedules such as twice weekly exploit irreversible inhibition rather than prevent tolerance.

Sourcing and Quality

  • Prescription status: Selegiline is prescription-only in the US and EU. Generic 5 mg oral tablets and capsules come from several approved manufacturers; brand products are Eldepryl, Zelapar and Emsam.
  • Formulation choice: Oral 5 mg generics are standard; low longevity doses need splitting or compounding. The orally disintegrating tablet and patch bypass first-pass metabolism and produce fewer amphetamine-type metabolites.
  • Compounding pharmacies: State-licensed compounding pharmacies can prepare 1 mg capsules or liquids on prescription; accreditation by the Pharmacy Compounding Accreditation Board signals independent quality oversight.
  • Gray-market products: Online “research chemical” deprenyl citrate liquids are unregulated, with unverified purity and dose; only a certificate of analysis from an independent laboratory offers any quality evidence.
  • Veterinary product: Anipryl is licensed for dogs, is dosed for animals and is not intended for human use.
  • Pharmacy verification: Online pharmacies can be checked through the National Association of Boards of Pharmacy “.pharmacy” verification or LegitScript certification to avoid counterfeits.

Practical Considerations

  • Time to effect: Mood benefit with the patch can appear within 1–2 weeks and builds over 6 weeks; Parkinson’s symptom relief appears within weeks. Any longevity effect cannot be observed in an individual.
  • Common pitfalls: Combining with dextromethorphan, tramadol or St John’s wort; dosing late in the day; assuming higher doses work better despite bell-shaped animal dose responses; overlooking oral contraceptives; forgetting that precautions last 2 weeks after stopping.
  • Regulatory status: US-approved for Parkinson’s disease (1989 tablet, 2006 orally disintegrating tablet) and major depression (2006 patch). Use for longevity or cognition in healthy adults is off-label; it is not a dietary supplement.
  • Cost and accessibility: Generic oral tablets are inexpensive, whereas the brand patch often exceeds US$1,000 per month without insurance. Some physicians are reluctant to prescribe it off-label for aging.
  • Payer and funding incentives: Because generic selegiline is off-patent and cheap, no company funds aging trials. Insurers usually require cheaper antidepressants to fail before covering the patented patch, a structural bias shaping access and research priorities.
  • Drug testing: Athletes and people subject to workplace testing face possible positive amphetamine screens; a documented prescription and chiral confirmation testing distinguish legitimate use.

Interaction with Foundational Habits

  • Sleep: Direct, disruptive. Amphetamine-type metabolites and higher dopamine tone increase insomnia, and higher doses suppress REM sleep (rapid-eye-movement, dreaming sleep) (Mayer et al., 1995). Morning-only dosing, no doses after noon and tracking time to fall asleep mitigate this.
  • Nutrition: Indirect. Food raises oral absorption about threefold, so consistent timing relative to meals keeps exposure stable. Tyramine limits apply only at higher doses; heavy caffeine adds stimulation. No nutrient depletion is known; the orally disintegrating tablet requires no food 5 minutes before and after.
  • Exercise: Indirect, potentially potentiating. Exercise also raises dopamine, and treated aged rodents kept better motor performance. No blunting of strength or endurance adaptations is known, but post-exercise heat and dehydration worsen orthostatic hypotension; hydration and rising slowly help.
  • Stress management: Direct. Heightened catecholamine activity can increase anxiety or agitation in sensitive people, while the patch reduces depressive symptoms. No cortisol effect is established; breathing practices, mindfulness and monitoring for jitteriness are practical complements.

Monitoring Protocol & Defining Success

Baseline testing before starting establishes blood pressure, heart rate, liver and kidney function, mood and cognition, and a full-skin examination, because these define the main risks and any later change. Baseline review also covers current oral contraceptive use and a complete medication and supplement list, screened for interactions.

Ongoing monitoring follows a set cadence: blood pressure (lying and standing) and sleep at 2 weeks and 3 months, then every 6–12 months; liver and kidney panels, mood score and cognitive screen every 12 months; and a full-skin examination yearly. Any new dizziness, hallucinations, compulsive behavior or severe headache triggers immediate review. Success is defined by tolerability and stable or improved function rather than by a longevity marker, since none has been validated for selegiline.

Biomarker Optimal Functional Range Why Measure It? Context/Notes
Seated blood pressure 110–120 / 70–80 mmHg Detect hypertension or hypotension Conventional target <130/80 mmHg; morning, seated 5 minutes, average of 2 readings
Orthostatic blood-pressure change Systolic drop <10 mmHg at 3 minutes standing Detect orthostatic hypotension Conventional cutoff ≥20 mmHg systolic or ≥10 mmHg diastolic drop; measure lying 5 minutes, then standing
Resting heart rate 50–70 beats/min Detect stimulant effect or arrhythmia Conventional 60–100 beats/min; pair with pulse regularity
ALT <25 U/L Liver function affects drug clearance ALT = alanine aminotransferase, a liver enzyme; conventional upper limit about 40–55 U/L; fasting not required
eGFR ≥90 mL/min/1.73 m² Kidney function affects metabolite clearance eGFR = estimated glomerular filtration rate, a kidney-filtration measure; conventional normal ≥60; pair with creatinine and cystatin C
PHQ-9 0–4 Track mood benefit and suicidality PHQ-9 = Patient Health Questionnaire-9, a validated depression score; 5–9 indicates mild depression; item 9 screens for suicidal thoughts
MoCA 26–30 Track cognitive stability MoCA = Montreal Cognitive Assessment, a validated cognitive screen; below 26 conventionally flags impairment; no established target for improvement, so change from own baseline is tracked
Full-skin examination No new or changing pigmented lesions Melanoma surveillance Dermatologist or trained clinician; photographs aid comparison

Qualitative markers:

  • Sleep quality and time to fall asleep
  • Daytime energy and motivation
  • Mood stability and absence of irritability or anxiety
  • Lightheadedness on standing
  • Mental clarity and focus
  • Libido and absence of compulsive urges

Emerging Research

  • Call for human aging studies: A 2025 meta-analysis of 22 rodent experiments concluded that clinical studies of health outcomes in older adults are the critical next step (Bene, 2025); no such trial is registered as of September 2026.
  • Reward processing in healthy volunteers: A University of Oxford study of single-dose selegiline on reward learning in 54 healthy adults (NCT04130087) could show whether low doses change motivation in people without disease; status unknown.
  • Daytime sleepiness in Parkinson’s disease: An open-label phase 4 study in 141 patients measured change in Epworth Sleepiness Scale (a validated sleepiness score) at 8 weeks (NCT04870372); completed, results unpublished.
  • Cancer add-on therapy: A phase 2 trial of selegiline plus docetaxel in 110 men with metastatic castration-resistant prostate cancer (prostate cancer that has spread and no longer responds to hormone-lowering therapy), primary endpoint freedom from progression at 9 months (NCT04586543), follows rat tumor-suppression data (Knoll et al., 2017).
  • New patch formulations: Phase 1 studies compare a new selegiline patch with Emsam for skin irritation in 232 healthy adults (NCT07452692) and for bioequivalence (matching blood levels) in 92 adults (NCT07571824), which could widen access and lower cost.
  • Survival data strengthening the case: A 2026 Korean national cohort linked early MAO-B inhibitor add-on therapy with 3.45 months longer 5-year restricted mean survival (average survival time within the 5-year window) in Parkinson’s disease, though allocation bias (treatment choice reflecting patients’ baseline health) is likely (Lee et al., 2026).
  • Evidence weakening the case: The US National Institute on Aging mouse study found MAO-B inhibition without survival benefit (Ingram et al., 1993), and a reanalysis of the dog survival study, run by the veterinary marketer Deprenyl Animal Health (Ruehl et al., 1997), lost significance after adjusting for age and sex (Bene, 2025).
  • Enhancer compounds: In rats, the related experimental enhancer compound BPAP (a benzofuran derivative) extended lifespan more potently than selegiline (Knoll & Miklya, 2016), suggesting future drugs may target the proposed enhancer mechanism without MAO-B blockade.

Conclusion

Selegiline is a long-established prescription drug that permanently blocks an enzyme which breaks down dopamine. For health-focused adults, its interest rests on a rare feature: repeated animal studies across several laboratories and species found longer average lifespan and better-preserved brain function in treated animals, and a recent combined analysis of those studies supports that signal. No study, however, has tested whether it extends life or health in healthy people.

Human evidence is strongest for relieving depression with the transdermal patch and for easing Parkinson’s symptoms, and weaker or mixed for stroke recovery, dementia and attention. Main risks at low doses are sleep disruption, dizziness on standing, dry mouth, and confusion or hallucinations in older or Parkinson’s patients. Serious reactions come mainly from combining it with certain antidepressants, opioid pain medications, cough suppressants or stimulants, or from higher doses. One early trial raised concern about deaths, but later combined analyses of several trials did not confirm it.

Much of the longevity case comes from the inventor’s own research group, and a veterinary maker ran the dog survival study; the depression patch trials were manufacturer-sponsored. The Life Extension Foundation, which discusses longevity dosing, sells supplements rather than this drug. Because the drug is cheap and off-patent, no company has reason to fund aging trials. The result is a well-characterized, generally tolerable drug with an intriguing but animal-only case for longer life.

Top - Benefits - Risks - Protocol